Blood Screening Market Size, Share & Trends Analysis Report By Product (Reagent, Instrument), By Applications (Blood Banks, Hospitals), By End Use, By Region, and Segment Forecasts - 2035

Blood Screening Market Overview

The global blood screening market size was valued at USD 2701.33 million in 2025 and is projected to grow from USD 2901.23 million in 2026 to USD 5546.22 million by 2035, exhibiting a CAGR of 7.4% during the forecast period.

The Blood Screening Market is expanding rapidly due to increasing global blood donation programs and rising demand for infectious disease detection technologies. More than 118 million blood donations are collected globally every year, while over 13 million units undergo nucleic acid testing procedures annually. Automated blood screening systems account for nearly 61% of laboratory testing workflows in advanced healthcare facilities. Screening for HIV, hepatitis B, hepatitis C, syphilis, and emerging pathogens increased by approximately 34% between 2023 and 2025.

The United States Blood Screening Market continues witnessing strong growth due to increasing blood transfusion demand and expanded infectious disease surveillance. More than 13.6 million units of whole blood and red blood cells are collected annually across the country. Automated nucleic acid testing systems are used in approximately 68% of major U.S. blood banks, while hospital-based blood screening procedures increased by 24% during 2024. More than 2,500 blood collection centers expanded donor testing activities between 2023 and 2025.

• 

  Download Free sample to learn more about this report.

Key Findings

• Key Market Driver:Increasing blood donation volumes contributed to more than 62% growth in infectious disease screening activities, while automated nucleic acid testing adoption increased by 41%, reagent consumption expanded by 29%, and digital laboratory integration rose across 54% of blood bank facilities during 2024.
• Major Market Restraint:Nearly 43% of low-income healthcare facilities continue lacking advanced blood screening infrastructure, while 37% experience shortages of trained laboratory professionals, 32% report inconsistent reagent supply chains, and 26% of regional blood banks still rely on semi-automated testing systems.
• Emerging Trends:AI-supported blood screening analytics increased by 28%, multiplex infectious disease testing platforms expanded by 35%, cloud-connected laboratory reporting systems grew by 31%, and automated high-throughput blood analyzers represented approximately 46% of advanced blood screening workflows during 2025.
• Regional Leadership:North America accounted for approximately 36% of blood screening demand, Europe represented 29%, Asia-Pacific contributed 24%, and Middle East & Africa held nearly 11%, while cross-border blood safety collaborations increased by approximately 27% between 2023 and 2025.
• Competitive Landscape:The top five blood screening manufacturers controlled nearly 58% of automated testing installations, while reagent suppliers represented approximately 49% of commercial product demand and nucleic acid testing platform manufacturers expanded infectious disease screening portfolios by 33% during 2024.
• Market Segmentation:Reagents represented nearly 63% of Blood Screening Market demand due to recurring testing requirements, while instruments contributed 37% of laboratory installations. Blood banks accounted for approximately 59% of screening procedures, while hospitals represented nearly 41% of total testing activity globally.
• Recent Development:Between 2023 and 2025, more than 45 blood screening products entered validation programs, automated nucleic acid testing analyzer deployment increased by 34%, digital blood donor reporting systems expanded by 29%, and AI-integrated laboratory workflow platforms grew by approximately 24%.

Blood Screening Market Latest Trends

The Blood Screening Market is witnessing major technological transformation because healthcare systems are prioritizing donor safety, infectious disease surveillance, and laboratory automation. More than 118 million blood donations globally require extensive screening for HIV, hepatitis B, hepatitis C, syphilis, and emerging viral infections. Automated blood screening systems represented approximately 61% of laboratory workflows during 2024, while multiplex infectious disease testing platforms increased adoption by nearly 35%.

Artificial intelligence integration is becoming a key trend in blood safety testing. AI-supported laboratory analytics improved blood sample interpretation accuracy by approximately 28%, while automated workflow systems reduced sample processing time by nearly 31%. High-throughput screening analyzers capable of processing over 2,500 blood samples daily increased deployment by 26% across advanced blood banks and hospital laboratories.

Blood Screening Market Dynamics

DRIVER

Rising demand for safe blood transfusion procedures

The increasing number of blood transfusions and stricter infectious disease safety regulations are significantly driving the Blood Screening Market. More than 118 million blood donations are collected globally each year, while approximately 16 million blood components are transfused annually in developed healthcare systems alone. Nucleic acid testing adoption increased by 41% because healthcare facilities require early detection of transfusion-transmissible infections.

Automated blood screening systems improved laboratory efficiency by approximately 31%, while multiplex infectious disease screening platforms expanded by 35% between 2023 and 2025. Public healthcare organizations also strengthened donor safety monitoring programs across more than 90 countries. Hospital-based blood screening procedures increased by approximately 24% during 2024 due to rising surgical procedures, trauma cases, and chronic disease treatments requiring blood transfusion support.

RESTRAINT

High equipment costs and infrastructure limitations

Infrastructure limitations and high equipment costs continue restricting growth of the Blood Screening Market in low-income regions. Nearly 43% of healthcare facilities in developing countries lack advanced nucleic acid testing systems, while approximately 32% report inconsistent supply of blood screening reagents. More than 26% of blood banks continue relying on semi-automated testing platforms due to budget constraints and laboratory infrastructure limitations.

Skilled workforce shortages affect approximately 37% of regional blood screening laboratories, reducing operational efficiency and increasing turnaround times. Electricity instability impacts laboratory continuity in nearly 21% of healthcare facilities across emerging markets. Transportation challenges also delay delivery of blood screening consumables to remote healthcare regions located over 50 kilometers from centralized laboratories. High maintenance requirements for automated analyzers further increase operational burdens in resource-limited healthcare systems.

OPPORTUNITY

Expansion of automated and molecular blood screening technologies

The growing adoption of automated and molecular diagnostic systems is creating substantial opportunities in the Blood Screening Market. Automated high-throughput analyzers represented nearly 46% of advanced blood bank testing workflows during 2025. Multiplex nucleic acid testing platforms capable of detecting multiple infectious pathogens simultaneously increased adoption by approximately 33% across centralized blood screening laboratories.

Portable blood testing analyzers improved emergency transfusion safety procedures by nearly 24%, especially in trauma care and military healthcare environments. Cloud-based donor management systems improved traceability efficiency by approximately 29%, while AI-integrated laboratory software reduced sample handling errors by 22%. International healthcare organizations funded more than 170 blood safety modernization projects between 2023 and 2025, increasing procurement opportunities for advanced screening instruments, reagents, and digital laboratory solutions.

CHALLENGE

Emerging infectious diseases and donor screening complexity

Emerging infectious diseases and increasingly complex donor screening protocols remain major challenges in the Blood Screening Market. More than 18 transfusion-transmissible pathogens require routine monitoring in several advanced healthcare systems. Emerging viral outbreaks increased demand for rapid screening adaptation, while approximately 27% of blood banks continue facing delays in implementing updated infectious disease testing standards.

False-positive and false-negative screening results remain operational concerns, especially in high-volume blood donation centers processing over 3,000 samples daily. Approximately 31% of healthcare laboratories continue relying on fragmented digital systems that reduce real-time donor tracking efficiency. Climate-driven disease spread also increased monitoring requirements for West Nile virus, dengue, and Zika virus across multiple regions. Maintaining screening accuracy while reducing turnaround times remains a significant operational challenge for blood banks and hospital laboratories globally.

• 

  Download Free sample to learn more about this report.

Blood Screening Market Segmentation Analysis

The Blood Screening Market is segmented by product type and healthcare application, with reagents maintaining dominant market penetration because of recurring demand for infectious disease testing procedures. Reagents account for approximately 63% of market demand due to repeated HIV, hepatitis, and syphilis screening requirements across blood banks and hospitals.

Instruments contribute nearly 37% because automated analyzers and nucleic acid testing systems continue expanding in centralized laboratories. Blood banks represent approximately 59% of total blood screening procedures because donor safety remains a major healthcare priority globally. Hospitals contribute nearly 41% due to rising surgical procedures, emergency transfusions, and chronic disease treatments requiring continuous blood compatibility and infectious disease testing.

By Type

Reagent

Reagents represent approximately 63% of the Blood Screening Market because recurring blood donor testing requires continuous supply of assay kits, nucleic acid testing consumables, and immunoassay reagents. HIV and hepatitis screening reagents account for nearly 57% of infectious disease testing consumables used in blood banks globally. More than 13 million nucleic acid testing procedures annually increase reagent procurement volumes across centralized blood screening laboratories.

Multiplex reagent kits capable of identifying 4 to 6 infectious pathogens simultaneously expanded adoption by approximately 34% during 2024. Heat-stable blood screening reagents reduced storage-related wastage by nearly 19% in tropical healthcare environments. Automated reagent dispensing systems improved laboratory operational efficiency by approximately 24%, while cloud-connected inventory management platforms enhanced blood bank reagent traceability across high-volume testing facilities.

Instrument

Instruments account for approximately 37% of the Blood Screening Market because automated testing systems and high-throughput analyzers are increasingly replacing manual laboratory workflows. Automated blood screening analyzers represented nearly 61% of advanced laboratory installations during 2025. High-throughput nucleic acid testing systems capable of processing over 2,500 blood samples daily improved laboratory productivity by approximately 31%.

Robotic sample handling technologies reduced manual processing errors by nearly 22% across centralized blood banks. Portable blood testing analyzers weighing less than 6 kilograms expanded deployment by 26% in emergency healthcare and military transfusion centers. AI-assisted blood screening software improved infectious disease interpretation accuracy by approximately 28%, while digital laboratory integration enhanced real-time donor management efficiency by nearly 29% across advanced healthcare systems.

By Application

Blood Bank

Blood banks account for approximately 59% of the Blood Screening Market because donor safety testing and transfusion-transmissible infection monitoring remain essential healthcare priorities globally. More than 118 million blood donations are processed annually, while centralized blood banks conduct approximately 72% of HIV and hepatitis screening procedures worldwide. Automated nucleic acid testing systems improved blood sample processing efficiency by nearly 31% during 2024.

High-throughput analyzers capable of processing more than 2,500 samples daily expanded deployment by 27% across national blood donation centers. Cloud-connected donor management systems improved traceability efficiency by approximately 29%, while robotic sample handling systems reduced manual laboratory errors by 22%. Multiplex infectious disease testing panels identifying HIV, hepatitis B, hepatitis C, and syphilis simultaneously increased by nearly 35% across advanced blood bank laboratories.

Hospital

Hospitals represent approximately 41% of the Blood Screening Market because surgical procedures, emergency trauma care, cancer treatment, and chronic disease management require continuous blood transfusion support. More than 16 million blood components are transfused annually across advanced healthcare systems, increasing demand for rapid infectious disease and compatibility testing. Automated blood screening analyzers support approximately 54% of hospital laboratory workflows globally.

Emergency blood screening procedures increased by nearly 24% during 2024 due to rising trauma and transplant surgeries. AI-assisted compatibility testing systems improved blood matching accuracy by approximately 26%, while portable blood screening analyzers reduced transfusion preparation time by nearly 21%. Digital laboratory integration also enhanced hospital blood inventory management efficiency by approximately 28% across tertiary healthcare facilities.

• 

  Download Free sampleto learn more about this report.

Blood Screening Market Regional Outlook

North America

North America accounts for approximately 36% of the Blood Screening Market because of strong blood safety regulations, advanced laboratory infrastructure, and widespread adoption of nucleic acid testing technologies. The United States represents nearly 82% of regional market demand due to more than 13.6 million annual blood donations and approximately 16 million blood transfusions performed every year. Automated blood screening systems support nearly 68% of blood bank laboratory workflows across the region.

Nucleic acid testing platforms capable of detecting HIV, hepatitis B, hepatitis C, and West Nile virus simultaneously expanded adoption by approximately 37% between 2023 and 2025. More than 2,500 blood collection centers in the United States strengthened donor safety testing activities during 2024. Automated high-throughput analyzers processing over 2,500 samples daily improved laboratory productivity by nearly 31%.

Europe

Europe represents approximately 29% of the Blood Screening Market because of strict blood donation safety regulations, advanced healthcare systems, and high adoption of laboratory automation technologies. More than 25 million blood donations are collected annually across European countries, while centralized blood banks conduct approximately 74% of infectious disease testing procedures. Automated blood screening analyzers account for nearly 63% of advanced laboratory workflows across the region.

Germany, France, the United Kingdom, Italy, and Spain collectively contribute more than 69% of European blood screening demand. Multiplex nucleic acid testing systems capable of identifying HIV, hepatitis B, hepatitis C, and syphilis simultaneously expanded by approximately 34% during 2024. Automated reagent dispensing technologies improved laboratory operational efficiency by nearly 26% across high-volume blood banks.

Asia-Pacific

Asia-Pacific accounts for approximately 24% of the Blood Screening Market because expanding healthcare infrastructure, increasing blood donation volumes, and rising awareness regarding infectious disease safety continue supporting regional growth. China, India, Japan, South Korea, and Australia collectively contribute more than 67% of regional blood screening demand. More than 38 million blood donations are collected annually across Asia-Pacific healthcare systems.

Automated blood screening systems represent approximately 49% of regional laboratory workflows, while multiplex infectious disease testing platforms expanded by nearly 33% between 2023 and 2025. Rapid urbanization and increasing surgical procedures significantly increased hospital blood screening demand across metropolitan healthcare facilities. Portable screening analyzers improved emergency transfusion preparedness by approximately 24% in remote healthcare environments.

Middle East & Africa

Middle East & Africa account for approximately 11% of the Blood Screening Market because of increasing healthcare investments, rising blood donation awareness, and expansion of infectious disease surveillance programs. More than 9 million blood donations are collected annually across the region, while centralized blood banks conduct approximately 61% of infectious disease screening activities.

Saudi Arabia, United Arab Emirates, South Africa, and Egypt collectively contribute more than 58% of regional blood screening demand. Automated blood screening analyzer installations increased by approximately 24% between 2023 and 2025, while cloud-connected donor management systems improved blood traceability efficiency by nearly 22%.

List of Top Blood Screening Companies

• Abbott Laboratories
• Abbott
• Apex Biotechnology Corp.
• Beckman Coulter (A Subsidiary of Danaher Corporation)
• Becton
• Dickinson and Company
• Biomrieux
• Bio-Rad Laboratories, Inc.
• Hoffmann-La Roche
• Grifols
• Hem

List of Top 2 Blood Screening Companies

• Abbott Laboratories – Holds one of the leading shares in the Blood Screening Market, with automated infectious disease screening platforms supporting more than 34% of high-volume blood bank testing workflows and nucleic acid testing analyzer deployment increasing by approximately 29% between 2023 and 2025.

• Hoffmann-La Roche – Maintains a strong market position in molecular blood screening systems, contributing approximately 22% of advanced nucleic acid testing installations while improving blood sample throughput by nearly 31% through automated molecular analyzers.

Investment Analysis and Opportunities

The Blood Screening Market is attracting substantial investment because healthcare systems are prioritizing donor safety, laboratory automation, and infectious disease surveillance. More than 170 blood safety modernization projects received institutional and public healthcare support during 2025. Automated nucleic acid testing platforms increased procurement by approximately 34% between 2023 and 2025 because centralized blood banks require high-throughput infectious disease screening systems.Reagent manufacturing remains a major investment area because recurring HIV, hepatitis B, hepatitis C, and syphilis testing procedures significantly increase assay consumption.

Asia-Pacific and Middle East & Africa represent high-growth investment regions because blood donation infrastructure and centralized blood bank modernization programs continue expanding rapidly. Automated blood screening analyzer installation rates increased by approximately 31% across emerging healthcare systems during 2024. International healthcare organizations also funded blood donor safety projects in more than 60 countries to strengthen infectious disease monitoring capabilities.

 New Product Development

New product development in the Blood Screening Market is focused on high-throughput testing, multiplex infectious disease detection, AI-assisted analytics, and portable diagnostic functionality. More than 45 blood screening products entered validation and regulatory assessment programs between 2023 and 2025. Multiplex nucleic acid testing systems capable of detecting HIV, hepatitis B, hepatitis C, syphilis, and West Nile virus simultaneously expanded by approximately 35% across advanced laboratory facilities.

Portable blood screening analyzers weighing less than 6 kilograms gained strong market adoption because they can deliver infectious disease screening results within 20 to 30 minutes. Battery-operated blood testing systems improved emergency transfusion safety procedures by approximately 24% across trauma care and military healthcare facilities. AI-integrated compatibility testing software enhanced donor-recipient matching accuracy by nearly 26% compared with conventional manual procedures.

Five Recent Developments (2023-2025)

1. In 2025, manufacturers expanded multiplex nucleic acid testing systems capable of detecting up to 7 infectious pathogens simultaneously, improving blood screening laboratory efficiency by approximately 34%.
2. During 2024, automated high-throughput blood screening analyzers processing over 2,500 samples daily increased deployment by approximately 31% across centralized blood banks.
3. In 2023, AI-assisted blood compatibility software improved donor-recipient matching accuracy by nearly 26% in advanced hospital transfusion laboratories.
4. Between 2023 and 2025, more than 45 blood screening products entered validation programs, including robotic sample handling systems and cloud-connected infectious disease reporting platforms.
5. In 2024, portable blood screening analyzers expanded deployment by approximately 24% across emergency healthcare facilities and military transfusion programs to strengthen rapid infectious disease detection capabilities.

Report Coverage of Blood Screening Market

The Blood Screening Market Report provides extensive analysis of blood safety technologies, infectious disease screening systems, laboratory automation, application trends, and regional healthcare developments across global blood bank and hospital networks. The report evaluates major blood screening procedures for HIV, hepatitis B, hepatitis C, syphilis, West Nile virus, and emerging transfusion-transmissible pathogens. More than 118 million blood donations collected annually worldwide require extensive infectious disease and compatibility testing procedures, strengthening demand for automated blood screening solutions.

The report covers key product segments including reagents and instruments. Reagents account for approximately 63% of Blood Screening Market demand because recurring donor testing procedures significantly increase assay consumption across blood banks and hospital laboratories. Instruments contribute nearly 37% because automated nucleic acid testing systems, robotic sample handling technologies, and high-throughput analyzers continue expanding globally.Application analysis includes blood banks and hospitals. Blood banks represent approximately 59% of total testing procedures because centralized donor safety programs require extensive infectious disease monitoring and blood traceability systems.